Gritti, Giuseppe http://orcid.org/0000-0002-6789-5123
Raimondi, Federico
Bottazzi, Barbara
Ripamonti, Diego
Riva, Ivano
Landi, Francesco
Alborghetti, Leonardo
Frigeni, Marco
Damiani, Marianna
Micò, Caterina
Fagiuoli, Stefano
Lorini, Ferdinando Luca
Gandini, Lucia
Novelli, Luca http://orcid.org/0000-0002-2705-248X
Morgan, Jonathan P.
Owens, Benjamin M. J.
Kanhai, Karan J. K.
Reljanovic, Gordana Tonkovic
Rizzi, Marco
Di Marco, Fabiano http://orcid.org/0000-0002-1743-0504
Mantovani, Alberto
Rambaldi, Alessandro http://orcid.org/0000-0002-3739-7502
Article History
Received: 1 April 2021
Accepted: 12 May 2021
First Online: 24 May 2021
Change Date: 28 June 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41375-021-01329-8
Compliance with ethical standards
:
: JPM, BMJO, and KJKK are employees of EUSA Pharma. AR reports consultancy fees from Amgen, Celgene, Gilead, Italfarmaco, Novartis, Omeros, Pfizer, and Roche; travel support from Amgen, Celgene, Gilead, Italfarmaco, Novartis, and Roche; and research grants from Amgen, Italfarmaco, and Roche. CM reports travel support from Medac. DR reports personal fees from Gilead, Janssen, and ViiV. FDM reports grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and Novartis; and personal fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Guidotti/Malesci, Menarini, Mundipharma, Novartis, Teva, and Zambon. GG reports non-financial support from Gilead Kite, Janssen, Roche, and Takeda; and personal fees from Amgen, Autolus, Gilead Kite, Italfarmaco, IQVIA, Roche, and Takeda. IR reports travel support from Aferetica. SF reports grants from Gilead and Novartis; and personal fees from AbbVie, Astellas, Bayer, Gilead, Intercept, Kedrion, Merck Sharp & Dohme, and Novartis. BB and AM are inventors of patents on PTX3 and obtain royalties on related reagents. The other authors declare no competing interests.
: We complied with all relevant ethical rules. The protocol and informed consent forms were approved by the Hospital Ethics Board at the Papa Giovanni XXIII Hospital in Bergamo, Italy. Patients, or their legal representative, provided either verbal or written consent to participate in the study.